Letter from the Editor

Dear Reader,


What started in psoriasis research has spread out to several inflammatory dermatoses: biologics and small molecules as targeted treatments. This innovation is empowering the dermatological practice with respect to the treatment of a myriad of inflammatory dermatoses.

In psoriasis and atopic dermatitis, a series of different biologics and small molecules are available. The lectures were focused on the adequate use in clinical practice of these treatments. We need to know better for which patients to prescribe which molecules and for how long.

The audience of AAD was happy to see the new options for a host of other inflammatory dermatoses besides psoriasis and atopic dermatitis. Lichen planus has not had an innovation for years, and now baricitinib was reported to be effective. Izokibep en bimekizumab proved to be effective in hidradenitis chronica suppurativa. Alopecia areata can be treated effectively with JAK inhibitors and the efficacy of deuruxolitinib was illustrated.

Delgocitinib was reported to be effective in chronic hand dermatitis. Vitiligo proved to improve on ruxolitinib and nemolizumab was effective in prurigo nodularis.

The treatment of inflammatory dermatoses is innovative. The question remains whether budget is available to implement these innovations in dermatological practice. It remains important that patients suffering from severe manifestations of these diseases all have important unmet needs. In costeffectiveness, the realisation of substantial improvements, and substantial gains in quality of life and health will justify increments in costs. The future of inflammatory dermatoses is bright.

Best regards,

Peter CM van de Kerkhof

 

Biography

Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was a board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement:Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma,Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant.Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.



Posted on 11 May 202311 May 2023